Home Cart Sign in  
Chemical Structure| 1415823-73-2 Chemical Structure| 1415823-73-2

Structure of Evobrutinib
CAS No.: 1415823-73-2

Chemical Structure| 1415823-73-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Evobrutinib is a highly selective inhibitor of the Bruton’s tyrosine kinase (BTK), which is important in the ­development and functioning of various immune cells including B ­lymphocytes and macrophages. Preclinical research suggests it may be therapeutically useful in certain autoimmune diseases.

Synonyms: M-2951; MSC-2364447C; M2951

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Evobrutinib

CAS No. :1415823-73-2
Formula : C25H27N5O2
M.W : 429.51
SMILES Code : C=CC(N1CCC(CNC2=NC=NC(N)=C2C3=CC=C(OC4=CC=CC=C4)C=C3)CC1)=O
Synonyms :
M-2951; MSC-2364447C; M2951
MDL No. :MFCD30502975
InChI Key :QUIWHXQETADMGN-UHFFFAOYSA-N
Pubchem ID :71479709

Safety of Evobrutinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Evobrutinib

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
PBMCs 0, 0.01, 0.1, 1, 10, 100, 1000 μg/mL 60 minutes Inhibition of B cell activation PMC6500888
BTK 2 μM 10 min To validate the labeling efficiency of evobrutinib derivatives on BTK PMC8662641
U937 NF-κB–Luc reporter cells 5 nM to 10 μM 30 minutes Inhibition of FcγR signaling PMC6500888
Healthy donor CD27- naive B cells 1 μM 11 days To study the effect of Evobrutinib on the differentiation of naive B cells into T-bet+ class-switched memory B cells, results showed that Evobrutinib diminished T-bet induction and class switching. PMC9462504
HMC3 cells 10 μM 12 hours BTK inhibition downregulated genes involved in microglial activation and cytokine release, including TLR4, NFKB1, RELA, NLRP3, IL6, and IL1B, while upregulating the microglial quiescence marker P2RY12. Additionally, BTK inhibition reduced the expression of iron-related genes TIM1, LRP1, DMT1, HAMP, and FTL, and increased the expression of the iron exporter FPN. PMC11328345
Jurkat cells 500 nM 2 hours Evaluate the labeling efficacy of Evo-2 in Jurkat cells, showing no BTK expression in Jurkat cells. PMC11867108
Ramos cells 500 nM 2 hours Evaluate the labeling efficacy of Evo-2 in Ramos cells, showing effective labeling of endogenous BTK. PMC11867108
Ramos B cells 0, 0.01, 0.1, 1, 10, 100, 1000 μg/mL 30 minutes Inhibition of BTK autophosphorylation after BCR activation PMC6500888
T cells 1 µM 30 minutes To assess the effect of Evobrutinib on T cell activation, results showed that Evobrutinib had no inhibitory effect on calcium mobilization in T cells. PMC7498502
B cells 1 µM 30 minutes To assess the effect of Evobrutinib on BCR-mediated B cell activation, results showed that Evobrutinib strongly inhibited intracellular calcium mobilization upon BCR ligation via anti-IgM. PMC7498502
Healthy donor peripheral blood B cells 1 μM 48 hours To study the effect of Evobrutinib on IFN-γ and CpG-ODN-induced T-bet expression, results showed that Evobrutinib attenuated the upregulation of T-bet. PMC9462504
Healthy donor CD27+ memory B cells 1 μM 6 days To study the effect of Evobrutinib on the differentiation of memory B cells into antibody-secreting cells (ASCs), results showed that Evobrutinib reduced ASC formation and IgG secretion. PMC9462504
HER2-negative breast cancer cell lines (MCF7, T47D, BT20, HCC1806) >5 µM (GI50) 72 hours Evaluate the antiproliferative effect of Evobrutinib on HER2-negative breast cancer cell lines, results showed no significant activity of Evobrutinib in these cell lines PMC10140101
HER2-positive breast cancer cell lines (BT474, SKBR3, AU565, EFM192A) >5 µM (GI50) 72 hours Evaluate the antiproliferative effect of Evobrutinib on HER2-positive breast cancer cell lines, results showed no significant activity of Evobrutinib in these cell lines PMC10140101

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice (C57BL/6J and SJL/J) Experimental autoimmune encephalomyelitis (EAE) model and cuprizone model of toxic de- and remyelination Oral gavage 10 mg/kg Daily for 14–41 days Evaluated the therapeutic effects of Evobrutinib in EAE and demyelination models, showing that Evobrutinib ameliorated clinical severity of EAE, reduced pro-inflammatory activation of microglia, and promoted clearance of myelin debris and remyelination. PMC11043151
SJL/J mice Experimental autoimmune encephalomyelitis (EAE) Oral gavage 10 mg/kg Once daily for 4 weeks To evaluate the effect of Evobrutinib on established meningeal inflammation. Results showed a significant reduction in meningeal contrast enhancement in the evobrutinib group compared to vehicle (30% reduction versus 5% increase; P=0.003). PMC8488383
Mice Collagen-induced arthritis (CIA) model Oral 1 mg/kg, 3 mg/kg Once daily for 15 days Evaluation of Evobrutinib efficacy in RA model PMC6500888
C57BL/6 mice Experimental autoimmune encephalomyelitis (EAE) Oral 1, 3, or 10 mg/kg Once daily for 7 days To assess the clinical and histological effects of Evobrutinib on EAE, results showed that Evobrutinib dose-dependently ameliorated clinical and histological EAE. PMC7498502

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03436394 Renal Impairment PHASE1 COMPLETED 2019-02-22 Please Contact the Merck KGaA ... More >>Communication Center, Darmstadt, 64293, Germany Less <<
NCT03725072 Healthy PHASE1 COMPLETED 2018-12-05 PRA Health Sciences, Groningen... More >>, 9728 NZ, Netherlands Less <<
NCT04314024 Healthy PHASE1 COMPLETED 2020-06-23 Nuvisan GmbH, Neu-Ulm, Germany
NCT03934502 Healthy PHASE1 COMPLETED 2019-06-12 Nuvisan GmbH, Neu-Ulm, 89231, ... More >>Germany Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.33mL

0.47mL

0.23mL

11.64mL

2.33mL

1.16mL

23.28mL

4.66mL

2.33mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories